EUVIMEDEUVIMED entdecken
Crossref

High fracture risk following discontinuation of anti-resorptive treatment due to medication-related osteonecrosis of the jaw in osteoporotic patients

Sophie Courtier, Frederic Balen, Maëva Masson, Arnaud Constantin, Adeline Ruyssen-Witrand, Michel Laroche, Yannick Degboé, Franck Delanoë, Guillaume Couture

Osteoporosis International · 16.11.2026

DOI: 10.1007/s00198-026-08063-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Osteoporosis International, online erschienen am 16.11.2026. Verfasst von Sophie Courtier und 8 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Centre, Toulouse University Hospital and University Toulouse III, Toulouse, France. courtier.s@chu-tououse.fr. Die Arbeit nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To our knowledge, the progression of osteoporosis and the associated fracture risk have never been studied in patients diagnosed with MRONJ secondary to ARDs for osteoporosis. Our study found a high frequency of fractures following MRONJ diagnosis and discontinuation of ARDs in these patients.

Introduction

Antiresorptive drugs (ARDs) are widely used to prevent osteoporotic fractures but can cause rare complications such as medication-related osteonecrosis of the jaw (MRONJ), often leading to discontinuation of therapy.

Objectives

This retrospective, monocentric, observational study aimed to study evolution of osteoporosis and fracture risk after MRONJ secondary to use of ARDs for osteoporosis.

Methods

Patients diagnosed with MRONJ related to an ARD for osteoporosis between January 1, 2012, and August 1, 2022, were identified within the Maxillofacial Surgery department of Toulouse University Hospital, France. Data concerning fractures, comorbidities, MRONJ and osteoporosis treatments was collected by reviewing subjects’ medical records.

Results

A total of 70 subjects (97% women) were included, with a mean age of 77 (± 8) years at the time of MRONJ, 60% having a history of osteoporotic fracture, 87% of taking bisphosphonates and 33% of taking denosumab. The cumulative duration of exposure to ARDs was 7.34 ± 4 years. ARDs had mostly been discontinued by the time of MRONJ (93%). Data on osteoporosis outcome was available for 55 patients, with a median follow-up time after MRONJ of 2.7 years (1.1 – 5.5). A new fracture was reported in 35% of patients (19/55). These were mostly severe fractures (65%), with a median fracture time of 2.8 years (1.4 – 4.5) after MRONJ and 2.1 years (1.4 – 4.5) after discontinuation of ARDs. Corticosteroid use was higher in the fracture group (42% vs 14%, p = 0.042), and follow-up duration was longer in the fracture group [4.5 years (1.9 – 8.6) vs 2.7 years (1.5 – 5.6), p = 0.08].

Conclusion

We found that 35% of patients experienced a fracture following MRONJ after discontinuation of ARDs, with a median delay of 2.1 years, suggesting that management of osteoporosis remains essential after the diagnosis of MRONJ.

Schlagwörter

Stichwörter der Autor:innen

Antiresorptive drugsBisphosphonateDenosumabFractureOsteonecrosis of the jawOsteoporosis

Autor:innen und Institutionen

  • Rheumatology Centre, Toulouse University Hospital and University Toulouse III, Toulouse, France. courtier.s@chu-tououse.fr.
  • Emergency Department, Toulouse University Hospital and University Toulouse III, Toulouse, France.
  • CERPOP-EQUITY, INSERM, Toulouse, France.
  • Rheumatology Centre, Toulouse University Hospital and University Toulouse III, Toulouse, France.
  • INFINITY-Toulouse Institute for Infectious and Inflammatory Diseases, INSERM UMR1291- CNRS UMR5051- University Toulouse III, Toulouse, France.
  • Centre d'Investigation Clinique de Toulouse CIC1436, Inserm, Team PEPSS, Toulouse, France.

Zitieren

APA

Courtier, S., Balen, F., Masson, M., Constantin, A., Ruyssen-Witrand, A., Laroche, M., Degboé, Y., Delanoë, F., & Couture, G. (2026). High fracture risk following discontinuation of anti-resorptive treatment due to medication-related osteonecrosis of the jaw in osteoporotic patients. Osteoporosis International. https://doi.org/10.1007/s00198-026-08063-w

Vancouver

Courtier S, Balen F, Masson M, Constantin A, Ruyssen-Witrand A, Laroche M, et al. High fracture risk following discontinuation of anti-resorptive treatment due to medication-related osteonecrosis of the jaw in osteoporotic patients. Osteoporosis International. 2026. doi:10.1007/s00198-026-08063-w

BibTeX
@article{Courtier2026,
  author = {Courtier, Sophie and Balen, Frederic and Masson, Maëva and Constantin, Arnaud and Ruyssen-Witrand, Adeline and Laroche, Michel and Degboé, Yannick and Delanoë, Franck and Couture, Guillaume},
  title = {High fracture risk following discontinuation of anti-resorptive treatment due to medication-related osteonecrosis of the jaw in osteoporotic patients},
  journal = {Osteoporosis International},
  year = {2026},
  doi = {10.1007/s00198-026-08063-w}
}
Kostenlos starten →